These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29089775)

  • 1. Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.
    Gerendash BS; Creel PA
    Onco Targets Ther; 2017; 10():5053-5064. PubMed ID: 29089775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
    Schmidinger M; Danesi R
    Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Schwartz G; Darling JO; Mindo M; Damicis L
    Target Oncol; 2020 Aug; 15(4):549-565. PubMed ID: 32770441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
    Osanto S; van der Hulle T
    Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
    Al-Salama ZT; Keating GM
    Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
    Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
    Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
    Choueiri TK; Pal SK; McDermott DF; Morrissey S; Ferguson KC; Holland J; Kaelin WG; Dutcher JP
    Ann Oncol; 2014 Aug; 25(8):1603-8. PubMed ID: 24827131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
    J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
    Tannir NM; Agarwal N; Porta C; Lawrence NJ; Motzer R; McGregor B; Lee RJ; Jain RK; Davis N; Appleman LJ; Goodman O; Stadler WM; Gandhi S; Geynisman DM; Iacovelli R; Mellado B; Sepúlveda Sánchez JM; Figlin R; Powles T; Akella L; Orford K; Escudier B
    JAMA Oncol; 2022 Oct; 8(10):1411-1418. PubMed ID: 36048457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
    Krawczyk K; Śladowska K; Holko P; Kawalec P
    Front Pharmacol; 2023; 14():1223929. PubMed ID: 37745049
    [No Abstract]   [Full Text] [Related]  

  • 15. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
    Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
    Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
    Grüllich C
    Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
    Singh H; Brave M; Beaver JA; Cheng J; Tang S; Zahalka E; Palmby TR; Venugopal R; Song P; Liu Q; Liu C; Yu J; Chen XH; Wang X; Wang Y; Kluetz PG; Daniels SR; Papadopoulos EJ; Sridhara R; McKee AE; Ibrahim A; Kim G; Pazdur R
    Clin Cancer Res; 2017 Jan; 23(2):330-335. PubMed ID: 27793960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study.
    Domański P; Piętak M; Kruczyk B; Jarosińska J; Mydlak A; Demkow T; Darewicz M; Sikora-Kupis B; Dumnicka P; Kamzol W; Kucharz J
    Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38398014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors.
    Poon DM; Chan K; Leung AK; Ng B; Cheung FY; Siu SW;
    Drugs Context; 2023; 12():. PubMed ID: 37378080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.